- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Impact of Single Nucleotide Polymorphism rs1799854 ABCC8 on Glibenclamide Glycemic Control in Patients with Type 2 Diabetes | ||
| Al- Anbar Medical Journal | ||
| Volume 22, Issue 2, April 2026, Pages 82-87 PDF (1.23 M) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2026.166446.2495 | ||
| Authors | ||
| Ameer Najah Mahdi* 1; Mohammed Ibrahim Rasool1; Hasan Hasan Murtadha AlKutubi2; Qasim Hamzah Marzah3 | ||
| 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq. | ||
| 2Imam Hassan Centre for Endocrinology and Diabetes, Karbala Health Department, Karbala, Iraq. | ||
| 3Department of Clinical Pharmacy, College of Pharmacy, University of Kerbala, Karbala, Iraq. | ||
| Abstract | ||
| Background: The incidence of type 2 diabetes mellitus (T2DM) in Iraq is rising continuously. Glibenclamide (GLB), which is a sulfonylurea member, is an important treatment for T2DM. The sulfonylurea receptor-1 is encoded by the ABCC8 gene, and its rs1799854 genetic variation may alter the hypoglycemic activities of GLB. Objective: To determine the rs1799854 polymorphism in the ABCC8 gene and assess its potential role in modifying the therapeutic response to GLB among T2DM patients. Materials and methods: An observational pharmacogenetic association study involved 120 T2DM patients on GLB medication who were screened for ABCC8 G>A (rs1799854) genotypes and glycemic health. Results: The wild type (GG) was detected in 21.67% of T2DM cases. The mutant type (AA) and the heterozygous type (GA) were detected in 37.5% and 40.83% of the cases, respectively. The results did not exhibit a significant difference among GG, GA, and AA genotypes regarding glycemic status parameters (HOMA 2-IR (1.24 ± 0.93 for GG genotype, 1.3 ± 2.98 for GA genotype, and 1.52 ± 1.79 for AA genotype), HOMA 2-%β (27.05 ± 39.75 for GG genotype, 22.3 ± 44.6 for GA genotype, and 25.8 ± 31.85 for AA genotype), and HbA1c (9.7 ± 3.75for GG genotype, 8.7 ± 2.65 for GA genotype, and 8.9 ± 2.35 for AA genotype) at P-value > 0.05. Conclusion: The ABCC8 G>A (rs1799854) genotype was significantly prevalent among individuals with T2DM. There was no discernible association between the ABCC8 G>A (rs1799854) genomic variant and GLB’s therapeutic effect. | ||
| Keywords | ||
| Type 2 diabetes mellitus; Glibenclamide; ABCC8 gene; Insulin | ||
| References | ||
|
[1] A.-M. Labib, A. P. Martins, J. F. Raposo, and C. Torre, "The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis," Diabetes Research and Clinical Practice, vol. 155, p. 107804, 2019.
[2] M. Abdul Basith Khan, M. J. Hashim, J. K. King, R. D. Govender, H. Mustafa, and J. Al Kaabi, "Epidemiology of type 2 diabetes—global burden of disease and forecasted trends," Journal of epidemiology and global health, vol. 10, pp. 107-111, 2020.
[3] U. Aliyu, S. M. Toor, I. Abdalhakam, M. A. Elrayess, A. B. Abou− Samra, and O. M. Albagha, "Evaluating indices of insulin resistance and estimating the prevalence of insulin resistance in a large biobank cohort," Frontiers in Endocrinology, vol. 16, p. 1591677, 2025.
[4] N. R. Hidayati, D. A. Perwitasari, I. N. Faridah, and R. Susilo, "Effect of Gene Polymorphisms on Oral Antidiabetic Drug Response in Patients With Type 2 Diabetes Mellitus," Sciences of Pharmacy, vol. 4, pp. 72-80, 2025.
[5] F. Baccetti, C. Crisafulli, F. Andreozzi, G. C. Mannino, A. Nicolucci, A. Michelli, et al., "Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years," Diabetes Research and Clinical Practice, vol. 214, p. 111781, 2024.
[6] E. De Franco, C. Saint‐Martin, K. Brusgaard, A. E. Knight Johnson, L. Aguilar‐Bryan, P. Bowman, et al., "Update of variants identified in the pancreatic β‐cell KATP channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes," Human mutation, vol. 41, pp. 884-905, 2020.
[7] C. G. Nichols, "KATP channels as molecular sensors of cellular metabolism," Nature, vol. 440, pp. 470-476, 2006.
[8] M. Li, S. Gong, X. Han, S. Zhang, Q. Ren, X. Cai, et al., "Genetic variants of ABCC8 and phenotypic features in Chinese early onset diabetes," Journal of Diabetes, vol. 13, pp. 542-553, 2021.
[9] N. A. ElSayed, G. Aleppo, V. R. Aroda, R. R. Bannuru, F. M. Brown, D. Bruemmer, et al., "Summary of revisions: standards of care in diabetes—2023," Diabetes Care, vol. 46, pp. S5-S9, 2023.
[10] S. H. Jung, "Stratified Fisher's exact test and its sample size calculation," Biom J, vol. 56, pp. 129-40, Jan 2014.
[11] D. Orozco-Beltran, M. Mata-Cases, S. Artola-Menéndez, F. Álvarez-Guisasola, A. Cebrián-Cuenca, and A. Pérez, "Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care," Primary Care Diabetes, vol. 19, pp. 7-14, 2025.
[12] J. L. Felton, D. Cuthbertson, M. Warnock, K. Lohano, F. Meah, J. M. Wentworth, et al., "HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants," Diabetologia, vol. 65, pp. 88-100, 2022.
[13] N. R. Kareem, A. U. Mosa, and A. M. R. Al-Juhiashi, "Impact of CYP2A6 genetic polymorphism on letrozole efficacy in Iraqi women with polycystic ovary syndrome," Journal of Taibah University Medical Sciences, vol. 20, pp. 439-449, 2025.
[14] R. I. H. Faraj and N. G. Al-Tawil, "Medication Adherence of Diabetic Patients in Erbil City: A Cross-Sectional Study," Al-Rafidain Journal of Medical Sciences (ISSN 2789-3219), vol. 9, pp. 110-117, 2025.
[15] A. M. R. Al-Juhaishi, T. H. Mousa, R. Mustafa, and R. Al-Shehristani, "Effect of cranberry in enhancing oral hypoglycemic agents in uncontrolled type-II diabetic patients," J Global Pharma Technol, vol. 10, pp. 319-24, 2019.
[16] M. Cai, Y. Li, M. Guo, H. Dong, and H. Cheng, "Multifaceted safety concerns of glibenclamide in managing type 2 diabetes: Evidence from real-world adverse event analysis," European Journal of Pharmacology, vol. 1005, p. 178113, 2025.
[17] M. Azimi, M. Paseban, S. Ghareh, F. Sharifi, F. Bandarian, and M. Hasanzad, "Association of ABCC8 gene variants with response to sulfonylurea in type 2 diabetes mellitus," Journal of Diabetes & Metabolic Disorders, vol. 22, pp. 649-655, 2023.
[18] M. Hanefeld, R. Patwardhan, N. P. Jones, and R. C. T. S. Group, "A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes," Nutrition, metabolism and cardiovascular diseases, vol. 17, pp. 13-23, 2007.
[19] A. E. S. d. Souza, C. H. S. d. Silva, R. d. C. S. d. Oliveira, A. P. A. Guimarães, A. N. L. M. d. Silva, I. G. Diniz, et al., "Investigation of genetic markers associated to type 2 diabetes mellitus in Santarém-Pará," Genetics and Molecular Biology, vol. 47, p. e20230107, 2024.
[20] P. Venkatachalapathy, S. Padhilahouse, M. Sellappan, T. Subramanian, S. J. Kurian, S. S. Miraj, et al., "Pharmacogenomics and personalized medicine in type 2 diabetes mellitus: potential implications for clinical practice," Pharmacogenomics and Personalized Medicine, vol. 14, pp. 1441-1455, 2021.
[21] I. G. Diniz, R. R. D. Noce, A. P. Pereira, A. N. L. M. d. Silva, E. R. P. Sacuena, R. B. Lemes, et al., "Common BMI and diabetes-related genetic variants: A pilot study among indigenous people in the Brazilian Amazon," Genetics and Molecular Biology, vol. 45, p. e20210153, 2022.
[22] H. R. Mohammed, R. B. Othman, Z. S. Hatef, M. K. B. Fradj, and H. Abdesselem, "Association of ABO Gene rs2073823 Polymorphism with Microvascular Complications, sP-Selectin Levels and Lipid Profile in Type 2 Diabetes," Curr Diabetes Rev, vol. 22, pp. 57-67, Jan 16 2025.
[23] M. Marushchak and I. Krynytska, "Insulin receptor substrate 1 gene and glucose metabolism characteristics in type 2 diabetes mellitus with comorbidities," Ethiopian Journal of Health Sciences, vol. 31, 2021.
| ||
|
Statistics Article View: 177 PDF Download: 154 |
||